Johnson & Johnson reported strong adjusted earnings and sales growth in Q4 and full-year 2017, supported by robust performance in Pharmaceuticals and strategic acquisitions. Despite a one-time tax charge, management's optimistic outlook for 2018 and continued investment in innovation are likely to bolster investor confidence in the short term.

[1]